Germline testing in community oncology patients with somatic BRCA1/2 mutations.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.1523
Abstract: 1523 Background: The primary purpose of tumor mutation profiling (TMP) is to molecularly characterize tumors to identify targeted treatments and improve outcomes, but it may also uncover germline mutations with implications for patients and families.… read more here.
Keywords: somatic brca1; germline testing; patients somatic; oncology ... See more keywords
Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation
Sign Up to like & getrecommendations! Published in 2023 at "Pharmacogenomics and Personalized Medicine"
DOI: 10.2147/pgpm.s397827
Abstract: Abstract PARP inhibitors (PARPi) are the maintenance therapy after first line platinum-based chemotherapy for patients with advanced epithelial ovarian cancer (EOC) with germline and pathogenic somatic BRCA1/2 mutations. However, as with chemotherapy, patients can develop… read more here.
Keywords: brca1; somatic brca1; chemotherapy; platinum based ... See more keywords
Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092435
Abstract: Simple Summary Our updated systematic review and meta-analysis investigates the frequency of germline and somatic BRCA1 and BRCA2 mutations in patients with prostate cancer (PC), with subgroup analysis according to the type of mutation (germline… read more here.
Keywords: germline; brca2; somatic brca1; analysis ... See more keywords